BioCentury | Nov 25, 2019
Clinical News

Months after NASH failure, more woes for CymaBay's lead product on safety

...two other companies have PPARδ-targeting products in clinical development. Reneo Pharmaceuticals Inc. has PPARδ agonist REN001...
BioCentury | May 20, 2019
Emerging Company Profile

Reneo: Small molecules for rare mitochondrial diseases

...niche in the rare genetic mitochondrial diseases space. Reneo Pharmaceuticals Inc. is developing PPARδ agonist REN001...
...therapies for the indications. Reneo said Monday it raised the series A to help advance REN001...
...improve insulin sensitivity and regulate inflammation. In initial Phase I studies and in animal models, REN001...
BioCentury | Apr 9, 2019
Company News

Fosun gains pair of cell therapies from ReNeuron

...cells. The therapy is in a U.S. Phase I/II trial to treat retinitis pigmentosa. ReNeuron's CTX stem cells...
...Group Co. Ltd. (Shanghai:600196; HKSE:2196) received the rights from ReNeuron. Hongjiang Li, Staff Writer CTX DP, CTX stem cells (ren001, CTX0E03 DP...
BioCentury | Mar 22, 2019
Product Development

Regulating regeneration in Europe

As Europe rethinks its policies on regenerative medicine, the question is whether it can regain its footing in a competitive field it once led, given the in-built inconsistencies across the EU’s member states. Europe positioned...
BioCentury | Feb 17, 2017
Clinical News

CTX stem cells: Ph II PISCES II data

...treatment showing that 3 of 21 patients who received a single dose of 20 million CTX stem cells...
...the 3 patients achieved the ≥2-point improvement at 3, 6 and 12 months post-treatment, respectively. CTX stem cells...
...CTX stem cells were well tolerated. ReNeuron Group plc (LSE:RENE), Pencoed, U.K. Product: CTX DP , CTX stem cells (formerly ReN001...
BioCentury | Jun 27, 2016
Clinical News

CTX DP: Completed Phase II enrollment

...ReNeuron completed enrollment in the open-label, U.K. Phase II PISCES II trial evaluating CTX DP comprised of...
...after an ischemic stroke. ReNeuron Group plc (LSE:RENE), Pencoed, U.K. Product: CTX DP , CTX stem cells (formerly ReN001...
BioCentury | Jul 20, 2015
Company News

Benitec, ReNeuron deal

Benitec and ReNeuron extended for one year an October 2014 deal to test the combination of Benitec’s DNA-directed RNAi (ddRNAi) gene silencing technology with ReNeuron’s CTX stem cell-derived exosomes to treat lung and drug-resistant cancers....
BioCentury | Jul 11, 2015
Financial News

Funding round-up: Atara, TherapeuticsMD, ReNeuron

...placement agent. ReNeuron expects data from an ongoing Phase II trial in 1H16 of its CTX stem cells...
BioCentury | May 5, 2014
Clinical News

Sotatercept: Additional Phase IIa data

Additional interim data from 18 evaluable patients with ESRD on hemodialysis in the 2-part, double-blind Phase IIa REN-001 trial showed that 37% of patients receiving 0.3 mg/kg subcutaneous sotatercept (n=8) and 40% of patients receiving...
BioCentury | Apr 14, 2014
Clinical News

ReN001: Phase II start

...plans to start an open-label, U.K. Phase II trial to evaluate a stereotaxic implantation of ReN001...
...post-stroke in up to 41 disabled stroke patients. ReNeuron Group plc (LSE:RENE), Guildford, U.K. Product: ReN001...
Items per page:
1 - 10 of 56